Camurus ABCAMRF -3.57%83 PS Ratio is 13.61 as of Jun. 30, 2026, which is 48% below its 10-year median of 25.96. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $69.05 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 935 Biotechnology companies, Camurus AB ranks worse than 60.21% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Camurus AB's share price is $54.00.
Camurus AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $3.97. Hence, Camurus AB's PS Ratio for today is 13.61.
The historical rank and industry rank for Camurus AB's PS Ratio or its related term are showing as below:
CAMRF'
s PS Ratio Range Over the Past 10 Years
Min: 10.77 Med: 25.96 Max: 105.55
Current: 14.78
During the past 13 years, Camurus AB's highest PS Ratio was 105.55. The lowest was 10.77. And the median was 25.96.
CAMRF's PS Ratio is ranked worse than 60.21% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs CAMRF: 14.78
Camurus AB revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Camurus AB was 9.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 31.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 44.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 40.60% per year.
During the past 13 years, Camurus AB's highest 3-Year average Revenue per Share Growth Rate was 108.80% per year. The lowest was -36.50% per year. And the median was 31.20% per year.
Back to Basics: PS Ratio
Camurus AB (OTCPK:CAMRF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Camurus AB PS Ratio Related Terms
Camurus AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Camurus AB's Share Price of today is $54.00. Camurus AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.97.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Camurus AB (CAMRF) has a PS Ratio of 13.61 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Camurus AB and its competitors. This is 48% below median its historical median of 25.96. Over the past decade, Camurus AB's PS Ratio has ranged from 10.77 to 105.55. According to the industry distribution chart, Camurus AB ranks #563 out of 935 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Camurus AB's PS Ratio too high?
Camurus AB's current PS Ratio of 13.61 is 48% below median its 10-year median of 25.96. Over the past 10 years, this metric has ranged from a low of 10.77 to a high of 105.55. The Biotechnology industry median PS Ratio is 9.37. Camurus AB's value of 13.61 is 45.3% above this industry median. Based on the distribution chart, Camurus AB ranks #563 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #563 out of 935 companies for PS Ratio. This places Camurus AB in the lower half of its industry. The industry median PS Ratio is 9.37. Camurus AB's value of 13.61 is 45.3% above this benchmark. Historically, Camurus AB's own PS Ratio has ranged from 10.77 to 105.55 over the past decade. While the company's 10-year median is 25.96 vs. the industry median of 9.37, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current PS Ratio of 13.61 is 45.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current PS Ratio is 13.61, which is 48% below median its own 10-year median of 25.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $69.05, compared to a current price of $54.00 — trading 21.8% below its estimated fair value. The current PS Ratio is 13.61, which is 48% below median its 10-year median of 25.96 and 45.3% above the Biotechnology industry median of 9.37. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Camurus AB (CAMRF), the current PS Ratio is 13.61 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 21.8% below its estimated GF Value™ of $69.05.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
PS Ratio: 13.61 (48% below median its 10-year median of 25.96)
GF Value™: $69.05 vs. price of $54.00 (21.8% below fair value)
Industry Position: 45.3% above the Biotechnology median (#563 of 935)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score
Get the complete analysis for CAMRF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
